Onkologie. 2026:20(3):141-145 | DOI: 10.36290/xon.2026.026

Radiation therapy for advanced prostate cancer

Igor Richter1, 2, 3, Josef Dvořák2
1 Onkologické oddělení, Krajská nemocnice Liberec
2 Onkologická klinika 1. LF UK a Fakultní Thomayerova nemocnice, Praha
3 Fakulta zdravotnických studií, Technická univerzita Liberec

Radiotherapy is an important treatment modalities for prostate cancer. It is most often used as the primary treatment of localized disease. Actually is discussed the role of radiotherapy in the treatment of advanced disease. The aim may be local irradiation of the prostate in the case of de novo diagnosed metastatic prostate cancer or local irradiation of metastases. Especially with the development of modern diagnostic methods, oligometastatic disease is being diagnosed. In these patients, targeted irradiation of metastases with a higher dose using stereotactic radiotherapy methods can be considered.

Keywords: prostate cancer, radiotherapy, metastasis, oligometastatic disease.

Accepted: June 15, 2026; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Richter I, Dvořák J. Radiation therapy for advanced prostate cancer. Onkologie. 2026;20(3):141-145. doi: 10.36290/xon.2026.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 1.7.2027

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Brno: Masarykova univerzita; 2005. Available from: http://www.svod.cz. Verze 7.0; 2007.
    2. Viani GA, Viana BS, Martin JEC, et al. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Cancer. 2016;122:2004-2011. Go to original source...
    3. Yu T, Zhang Q, Zheng T, et al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS One. 2016;11:e0154499. Go to original source...
    4. Wortel RC, Incrocci L, Pos FJ, et al. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. Int J Radiat Oncol Biol Phys. 2016;95:680-689. Go to original source...
    5. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415-1419. Go to original source...
    6. Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110:104-109. Go to original source...
    7. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44:265-276. Go to original source...
    8. Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57:315-321. Go to original source...
    9. Martens C, Pond G, Webster D, et al. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy. 2006;5:9-13. Go to original source...
    10. Machtens S, Baumann R, Hagemann J, et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol. 2006;24:289-295. Go to original source...
    11. Hoskin PJ, Colombo A, Henry A, et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol. 2013;107:325-332. Go to original source...
    12. Galgano SJ, McDonald AM, West JT, et al. Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer. Cancers (Basel). 2022;14:3302. Go to original source...
    13. Bonaddio J, Carll J, Eapen R, et al. The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer. BJU Int. 2026;137:49-57. Go to original source...
    14. Gillessen S, Bossi A, Davis ID. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023;83:267-293. Go to original source...
    15. Boeve LMS, Hulshof MCCM, Vis AN, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-418. Go to original source...
    16. Boevé LMS, Hulshof MCCM, Verhagen PCMS, et al. Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial. Eur Urol. 2025;87:357-363. Go to original source...
    17. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36:1080-1087. Go to original source...
    18. Parker CC, James ND, Brawley CD et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353-2366. Go to original source...
    19. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine. 2022;19:e1003998. Go to original source...
    20. Fizazi K, Foulon S, Carles J et al. PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399:1695-1707. Go to original source...
    21. Roessler N, Miszczyk M, Dematteis A, et al. Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials. Clin Transl Radiat Oncol. 2025;54:101009. Go to original source...
    22. Rusthoven CG, Jones BL, Flaig TW, et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016;34:2835-2842. Go to original source...
    23. Muldermans JL, Romak LB, Kwon ED, et al. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;95:696-702. Go to original source...
    24. Ost P, Reynders D, Decaestecker K, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018;36:446-453. Go to original source...
    25. Phillips R, Shi WY, Deek M,et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6:650-659. Go to original source...
    26. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051-2058. Go to original source...
    27. Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135. Go to original source...
    28. Bowden P, See AW, Frydenberg M, et al. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Int J Cancer. 2020;146:161-168. Go to original source...
    29. Francolini G, Allegra AG, Detti B, et al. ARTO Working Group members. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol. 2023;41:5561-5568. Go to original source...
    30. Zhang H, Orme JJ, Abraha F, et al. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021;27:6376-6383. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.